Contribute Try STAT+ Today

A stealth biotechnology company that has attracted curiosity and speculation because of its eminent co-founders emerged into the spotlight on Thursday with the announcement of its first scientific discovery — a CRISPR-associated enzyme that promises several advantages over other ones — and an explanation of where it hopes to find scientific riches.

Arbor Biotechnologies, said co-founder David Walt of Brigham and Women’s Hospital and Harvard, wants to scour the microbial world — “this uncharted region,” he calls it — in search of molecules “that will benefit humans in health, agriculture, and the environment.” The startup is premised on the idea that “microbes have developed an incredible diversity of chemical and biochemical solutions to the myriad environmental challenges they encounter,” he told STAT.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.